Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature
We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and support...
| Autores: | , , |
|---|---|
| Tipo de documento: | artigo |
| Estado: | Versão publicada |
| Data de publicação: | 2021 |
| País: | Perú |
| Recursos: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Repositório: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Idioma: | espanhol |
| OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/821 |
| Acesso em linha: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821 |
| Access Level: | Acceso aberto |
| Palavra-chave: | COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| Resumo: | We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocilizumab, anakinra and baricitinib, against COVID-19. It is expected that they will provide support for future treatments. and research on the disease. |
|---|